HGS' repifermin starts Phase IIb in ulcers
Human Genome Sciences has started a Phase IIb trial of repifermin, alsoknown as keratinocyte growth factor-2, in patients with chronic venous ulcers. The 700-patient Closing Venous Ulcers with Repifermin (CLOSURE) study will compare a topical formulation of repifermin to placebo, administered for up to 26 weeks in addition to standardized compression therapy and wound care, with the primary endpoint being complete closure of the lesion.
Repifermin is the lead drug in HGS' genomics-based drug discovery program, and was licensed to SmithKline Beecham (now GlaxoSmithKline) last year, after generating positive results in a Phase IIa trial in venous ulcers (Marketletters September 18 and October 23, 2000).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze